🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 26 Guangzhou 23 Shanghai 15 Hangzhou 13 Wuhan 13
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University451 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University181 Nanfang Hospital, Southern Medical University138 AstraZeneca133 Guangdong Provincial People's Hospital81 Clear sponsor filter
Site location
Beijing26 Guangzhou23 Shanghai15 Hangzhou13 Wuhan13
All 57 locations
Target enrolment
to

Trials with a site in Guangzhou

23 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
NCT07646678Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
Takeda
Phase 2/3
500
Xicheng, Guangzhou, Zhenzhou
2026-06-11
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
NCT07633301Narcolepsy Type 1
Takeda
Phase 2
92
Beijing, Guangzhou, Zhengzhou
2026-06-04
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
Takeda
Phase 3
1,182
Bengbu, Beijing, Guangzhou, Wuhan, Zhuzhou, Baotou Shi, Pingxiang, Linyi Shi
2026-03-11
Recruiting
A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome
NCT07319832Short Bowel Syndrome (SBS)
Takeda
Observational
12
Guangzhou, Shanghai, Hangzhou
2026-03-05
Recruiting
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263Hidradenitis Suppurativa
Takeda
Phase 2
90
Beijing, Guangzhou, Wuhan, Shanghai, Hangzhou
2026-01-26
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
Takeda
Phase 3
110
Beijing, Guangzhou, Changsha, Hangzhou, Shanghai
2025-12-04
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301IO-resistant sqNSCLC
Takeda
Phase 3
600
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Xinxiang
2025-11-26
Recruiting
A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)
NCT07129343Von Willebrand Disease (VWD)
Takeda
Phase 3
20
Beijing, Guangzhou, Jihan, Shanghai, Suzhou, Tianjin, Wuhan
2025-10-13
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangzhou, Shenzhen, Changsha, Baotou, Nanjing
2025-07-15
Recruiting
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615Crohn's Disease, Ulcerative Colitis
Takeda
Phase 2
192
Chongqing, Guangdong, Guangzhou, Shanghai
2025-05-28
Recruiting
A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
NCT06952699Narcolepsy Type 2
Takeda
Phase 2
88
Beijing, Guangzhou, Changchun, Shanghai
2025-05-06
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
Takeda
Phase 3
600
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections
NCT06439342Cytomegalovirus (CMV)
Takeda
Phase 3
20
Hefei, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Beijing, Tianjin
2024-12-16
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461Crohn's Disease
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Recruiting
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
NCT05837897Crohn's Disease
Takeda
Phase 3
408
Hefei, Wuhu, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Huizhou
2023-06-16
Active, closed
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
NCT05673785Lymphoma
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Active, closed
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
NCT04129502Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Takeda
Phase 3
354
Beijing, Zhengzhou, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Shanghai
2020-01-10
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Rows per page Showing 1–23 of 23
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 23 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

18 of the 23 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 5 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 23 studies
PhaseStudiesRecruitingShare
Phase 3141160.9%
Phase 27530.4%
Observational114.3%
Phase 2/3114.3%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Takeda2318
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.